Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 1;48(9):477-478.
doi: 10.1097/COC.0000000000001208. Epub 2025 Aug 22.

Letter to Editor on Qureshi et al. Efficacy and Safety of Abemaciclib in Combination with Endocrine Therapy for HR+/HER2- Advanced or Metastatic Breast Cancer a Systematic Review and Meta-Analysis, Am J Clin Oncol, 2025, 48(1)

Rana H Shembesh  1 , Mohammed S Beshr  2 , Muhammed Elhadi  3
Affiliations

Letter to Editor on Qureshi et al. Efficacy and Safety of Abemaciclib in Combination with Endocrine Therapy for HR+/HER2- Advanced or Metastatic Breast Cancer a Systematic Review and Meta-Analysis, Am J Clin Oncol, 2025, 48(1)

Rana H Shembesh et al. Am J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Qureshi Z, Jamil A, Fatima E, et al. Efficacy and safety of abemaciclib in combination with endocrine therapy for HR+/HER2- advanced or metastatic breast cancer: a systematic review and meta-analysis. Am J Clin Oncol. 2025;48:6–15.
    1. Inoue K, Masuda N, Iwata H, et al. Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. Breast Cancer. 2021;28:1038–1050.
    1. Kaufman PA, Toi M, Neven P, et al. Health-related quality of life in MONARCH 2: abemaciclib plus fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. Oncologist. 2020;25:e243–e251.
    1. Toi M, Huang CS, Im YH, et al. Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: overall survival from MONARCH 2. Cancer Sci. 2023;114:221–226.
    1. Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with hr+/her2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35:2875–2884.

LinkOut - more resources